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ABSTRACT
Introduction: Within the hyperthermia community, consensus exists that clinical outcome of the treat-
ment radiotherapy and/or chemotherapy plus hyperthermia (i.e. elevating tumor temperature to
40 44 C) is related to the applied thermal dose; hence, treatment quality is crucial for the success of
prospective multi-institution clinical trials. Currently, applicator quality assurance (QA) measurements
are implemented independently at each institution using basic cylindrical phantoms. A multi-institu-
tion comparison of heating quality using magnetic resonance thermometry (MRT) and anatomical rep-
resentative anthropomorphic phantoms provides a unique opportunity to obtain novel QA insights to
facilitate multi-institution trial evaluation.
Objective: Perform a systematic QA procedure to compare the performance of MR-compatible hyper-
thermia systems in five institutions.
Methods and materials: Anthropomorphic phantoms, including pelvic and spinal bones, were pro-
duced. Clinically relevant power of 600 watts was applied for 12min to allow for 8 sequential MR-
scans. The 3D-heating distribution, steering capabilities, and presence of off-target heating
were analyzed.
Results: The evaluated devices show comparable heating profiles for centric and eccentric targets.
The differences observed in the 3D-heating profiles are the result of variations in the exact phantom
positioning and applicator characteristics, whereby positioning of the phantom followed current
ESHO-QA guidelines.
Conclusion: Anthropomorphic phantoms were used to perform QA-measurements of MR-guided
hyperthermia systems operating in MR-scanners of different brands. Comparable heating profiles are
shown for the five evaluated institutions. Subcentimeter differences in position substantially affected
the results when evaluating the heating patterns. Integration of advanced phantoms and precise posi-
tioning in QA-guidelines should be evaluated to guarantee the best quality patient care.
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Introduction
Hyperthermia (HT), the elevation of tumor temperature to a
supraphysiological level in the range of 40–44 C, is an effect-
ive radiation- and chemo-sensitizer. Randomized clinical trials
have reported significant improvements in the clinical out-
come when HT is added to standard oncological treatment
regimens of radiation and/or chemotherapy [1]. The addition
of HT has proven effective in melanoma [2], soft tissue sar-
coma [3], pediatric tumors [4], head and neck [5], esophageal
[6], recurrent breast [7,8], bladder [9] and cervical [10,11]
cancers. In these clinical trials, QA measurements were
performed independently in each institution and were
non-comparable. The existence of a thermal dose–effect
relationship [12–15] strongly supports identical QA
measurements among institutions to determine whether
clinical results using these different systems can be meaning-
fully combined in multi-institution clinical studies [16].
We recently demonstrated that magnetic resonance
thermometry (MRT) measurements, as facilitated by
MR–radiofrequency (RF) hyperthermia systems, provide
unprecedented 3D QA capabilities [17]. However, an
anthropomorphic and human-shape representative phantom
has not yet been utilized to compare results of multiple clin-
ically active MR-compatible systems.
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Magnetic resonance (MR)-guided HT (MR-HT) is considered
the latest HT technology, and the BSD-2000-3D MR-compat-
ible applicators are the only radiofrequency-based applica-
tors that are clinically used for the treatment of deep pelvic
cancers and those of the extremities. MR-compatible ultra-
sound-based applicators are also clinically used for the treat-
ment of deeply seated cancers. While ultrasound technology
was initially proposed to ablate (>60 C) small tumors, the
introduction of both electrical and mechanical steering of
the focus energy has facilitated adaptation of the systems to
allow the application of hyperthermia to larger tumors. An
extensive review of ultrasound technology can be found
elsewhere [18]. The first radiofrequency-based 1.5 T MR-HT
hybrid system (named ‘Sigma Eye,’ Pyrexar Medical Corp., UT,
USA) was installed in 2000 at the Charite Berlin, widely
tested conducting phantom measurements, and subse-
quently clinically validated [19,20]. This early and extensive
QA work on the MR-HT hybrid system in a single institute
included the use of a novel 3D phantom, and has been pub-
lished by Gellerman et al. [21,22] and Weihrauch et al. [23].
Based on this work, identical MR-HT hybrid systems were
installed in the University Hospitals of D€usseldorf, Erlangen,
and T€ubingen between 2007 and 2011 to operate within a
Siemens-Symphony MR-system (Siemens Healthineers,
Erlangen). A newer version of this applicator was installed in
the Erasmus MC Cancer Institute in 2014 to operate inside a
GE-Optima-450W MR-system (GE, Boston, MA, US). The latest
generation of these applicators, the ‘Universal Applicator,’
was installed in the University Hospital of Munich in 2017 to
operate within a Philips Ingenia MR-system (Philips,
Amsterdam, The Netherlands). Each MR-HT hybrid system pro-
vides 3D-steering of the heating pattern together with nonin-
vasive MRT for monitoring of the achieved temperature
distribution. These MRT monitoring capabilities also provide
an unmatched tool for 3D quality assurance (QA) [17]. Such
novel QA procedures in hyperthermia treatments may provide
new insights into the possible level of assurance of uniform
quality of hyperthermia treatment delivery and monitoring
among multiple institutions contributing to a clinical trial [16].
To make the first inventory of the performance of the five dif-
ferent MR-hybrid BSD2000-3D systems installed in Europe, we
initiated two studies. The first study focused on performing a
quantitative evaluation of the differences between the tem-
peratures measured by MRT and thermistor probes and is
reported in Curto et al. [24]. The current, i.e. second, study,
focuses on the evaluation of the heating patterns generated
by the different BSD-2000-3D MR-compatible applicators.
Wust et al. [25] evaluated the performance of the non-MR-
compatible BSD-2000-2D Sigma-60 applicator (Pyrexar Medical
Corp., UT, USA) in four European hyperthermia institutions
using the lamp phantom. A frequency-dependent defocussing
of heating patterns was detected in all four systems, and it
was concluded that a universal procedure for quality control
is required. Bruggmoser et al. [26,27] provided practical QA
guidelines for the application of deep HT using non-MR-com-
patible systems and recommended verification of the func-
tionality of the HT system using phantoms. Such QA
guidelines have not yet been established for MR-HT systems.
Several authors have evaluated the performance of spe-
cific non-MR-compatible BSD-2000 [28,29] and BSD-2000-3D
[24,30,31] applicators. Previously, the Charite Berlin hyper-
thermia group reported the results of their QA testing in an
MR-HT hybrid system using a cylindrical phantom and an
inhomogeneous elliptical phantom containing a skeleton.
MRT profiles were compared with direct temperature meas-
urements [21] and planning calculations [22,23]. Additionally,
the influence of various parameters was discussed as a local
drift of the static magnetic field B0 and amplitude and phase
at the antenna’s feed point. The effect of anatomical body
contour and shape on system performance has previously
been evaluated by numerical models but experimental verifi-
cation remains lacking [32,33]. In subsequent work, Wyatt
et al. [34] evaluated the heating performance of the mini-
annular phased array applicator (MAPA) and breast applicator
with homogeneous and inhomogeneous phantoms. It was
found that MR-system drifts can be appropriately corrected
using oil-based references.
The primary goal of a QA hyperthermia program is to
establish a minimum level of quality in hyperthermia treat-
ments [35]. QA guidelines have been introduced for regional
deep hyperthermia [26,27,36]. More recent QA guidelines
have been formulated by the technical committee of the
European Society for Hyperthermic Oncology (ESHO) [37] for
superficial [35,38] and interstitial [39] hyperthermia. Current
standards of QA as issued by the ESHO are based on measur-
ing the temperature increase patterns in simple geometric
homogenous phantoms [26,27,35,36,38,39]. The design of
these new QA protocols is based on the principle that a min-
imum level of QA should be feasible with the components
available in the commercial hyperthermia equipment. In
practice, this means that QA measurements are at best
obtained in 2D along the main axes if infrared thermography
with split phantoms or direct E-field measurement systems
are used [35]. When QA is performed with the standard
hyperthermia equipment, the number of temperature sensors
is limited (the minimum is 5 sensors); and when using the
same phantom, the time interval between experiments is
long (>10 h) since the phantom needs to stabilize its tem-
perature after each experiment. Consequently, the precision
(spatial and numerical) in assessing the quality assurance of
a hyperthermia system is not at the same level as that in
radiotherapy. Such a precision will most likely not be neces-
sary, although discussion on the final requirements remains
ongoing. Current state-of-the-art QA procedures, such as sin-
gle-point thermometry or 2D-QA tools like lamp phantoms,
LEDs, e-field sensors, or infrared thermometry, cannot pro-
vide 3D-visualisation of the heating profiles in anthropo-
morphic phantoms. Performing sequential measurements
with the matrix containing a lamp, LEDs, or e-field sensors at
different positions can provide 3D-visualisation only in
homogeneous phantoms. Additionally, infrared thermometry
is limited to split phantoms. In summary, no 2D-QA approach
is suitable for describing or explaining clinically rele-
vant features.
To facilitate QA control in multi-institution studies, we
performed systematic and rigorous QA measurements in all
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currently clinically used MR-HT hybrid systems (University
Hospitals of D€usseldorf, Erlangen, Munich, and T€ubingen in
Germany, and the Erasmus MC Cancer Institute, Rotterdam,
The Netherlands), as shown in Figure 1. For this purpose,
phantoms with a representative anthropomorphic shape
were developed and new evaluation methods are presented.
To evaluate the steering capabilities of the applicators, meas-
urements were performed with the aim of centric and eccen-
tric focusing in each of the institutions. The long-term aim of
this work was to contribute to the development of QA
guidelines for MR-guided hyperthermia; thus, the current
manuscript should be seen from this perspective. It reports
the first experiences of comparing the QA performance
among the BSD-2000-3D MR-compatible applicators while
following the current QA guidelines but using a 3D tempera-
ture measurement device (MR-thermometry).
Methods and materials
Hyperthermia and magnetic resonance systems
The MR-compatible Sigma-Eye applicators have been
designed and built following a custom-specific design to
operate within Siemens and GE MRs. The MR-compatible
Universal Applicator has been specifically designed to pro-
vide a standardized and reproducible applicator capable of
operating within any 1.5 T MR-system [40]. Both
hyperthermia applicators, the Sigma-Eye and the Universal
Applicator, operate at 100MHz and consist of three rings of
antennas with four dipole-pairs per ring. Optimized ampli-
tude and phase can be delivered to each of the twelve
dipole-pairs to provide 3D-steering of energy. Dedicated fil-
ters are implemented to decouple the operating frequencies
of the HT- (100MHz) and MR-system (63.5MHz), preventing
system cross-talk as a basis for simultaneous heating and
imaging [21]. Both applicators contain a bolus that is posi-
tioned between the antennas and the patient. The bolus is
filled with deionized water for efficient transfer of electro-
magnetic energy from the antennas to the patient, in add-
ition to cooling the patient surface.
Phantom development
A mannequin with a realistic male shape and dimensions
and a wall thickness of 4mm was used as a shell for the
new anthropomorphically shaped phantom. The transverse
dimensions of the mannequin were 352 213mm. Artificial
plastic pelvic bones, spinal bones and disks of a full-body
anatomical skeleton (VM101, Vosmedisch, Amsterdam, The
Netherlands) were fixed in the interior of the shell. The
dielectric properties of the mannequin shell and artificial
bones were a relative permittivity of 2.8 and an effective
conductivity of 0 S/m at 100MHz. Closed-tip sterile catheters
Figure 1. Sigma-Eye MR-compatible and Universal MR-compatible hyperthermia applicators (Pyrexar Medical Corp., UT, U.S.) operating inside Siemens (A C), GE
(D), and Philips (E) MR-scanners in the different institutions. Order does not reflect institution numbers.
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were positioned inside and around the bone structure to
facilitate the insertion of high-resistance thermistor probes,
as shown in Figure 2. Further details of the phantom con-
struction can be found in Curto et al. [24]. The phantom shell
was filled with a mixture of sodium benzoate, agar, and
deionized water (10 g sodium benzoate and 20 g agar per
1000 g deionized water). Sodium benzoate was used to
adjust the conductivity and as a preservative agent. The
dielectric properties of the phantom were measured using a
Dielectric Assessment Kit (DAK, Speag, Zurich, Switzerland) at
21 C. The measured values were a relative permittivity of
78.6 ± 0.03 and an effective conductivity of 0.41 ± 0.0002 S/m
at 100MHz. The relative permittivity of the phantom material
was larger than the average value within the human pelvis,
which can potentially reduce the focus size and amplify dif-
ferences as compared with actual clinical treatments or varia-
tions among the systems. These relative permittivity and
conductivity values are within the range used in previous
studies [17,41]. A phantom with a lower conductivity value
was also proposed in the latest ESHO QA guidelines for deep
hyperthermia [27]. The center of the phantom was deter-
mined and labeled on the surface. For the experiments, the
center of the phantom was aligned with the center of the
applicator and MR-system. Two phantoms were produced
following the same procedure and using the same materials.
The manual process of the production procedure may lead to a
small difference between the two phantoms regarding the posi-
tioning of the bone structure within the mannequin shell. Only
one measurement can be performed per phantom per day due
to the need to cool down and stabilize the temperature of the
phantom; therefore, two phantoms were produced. One of the
phantoms was used to evaluate focus-steering for a centric
target and the other phantom was used to evaluate focus-
steering for an eccentric target [24].
QA measurements
The QA measurements aimed to assess the performance of
the five hyperthermia applicators under clinically representa-
tive conditions, with the phantom measurements and condi-
tions being as similar as possible in all institutions. We aimed
for a positioning error to be as low as possible, preferably
below 10-mm uncertainty, as is the requirement in the ESHO
guidelines [27]. The water flow within the water bolus was
deactivated to reduce artifacts due to water motion. The
only residual parameter was the room temperature, which
was slightly different among the five institutions; therefore,
the phantoms were stored in the MR room the day prior to
performing the measurements to avoid any residual tem-
perature gradients between the phantom and the MR room.
Samples of deionized water were collected from the water
tank used to fill the water bolus in each institution. These
samples were stored in sterilized 250-ml containers until trip-
licate measurements were performed on the same day with
a DAK at 21 C. The MR room and water bolus temperatures
were recorded before starting each measurement.
In the Sigma-Eye applicator, the phantom was positioned
in the hammock (Figure 1(A–D)). Using the Universal
Applicator, the phantom was positioned on the applicator
mattress (Figure 1(E)). The positioning was verified at the
center of the phantom by high-resolution MR scanning.
All the systems are maintained by a service contract with
the supplier (Dr. Sennewald Medizintechnik GmbH, Munich,
Germany), and verification of the central focus is usually
Figure 2. Anthropomorphic phantom (A), with schematic cross-section of the positioning of the phantom inside the MR scanner and monitoring of the central
axial slide (B), and sequence of the performed MR scans and HT power (C).
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performed with a lamp phantom. Regular (bimonthly) QA
procedures include phase and amplitude calibrations and
heating tests. The power amplitude and phase calibration
processes of the BSD-2000-3D MR-compatible applicators
have built-in checks to help ensure calibration accuracy. The
treatment control processes include additional checks to
ensure that the system remains stable enough for use,
including continuous monitoring of the measured phase and
power levels. The design of the system for phase calibration
includes the calibration of both the phase detection and
phase shifters; therefore, the desired phase for each channel
relies on these two separate functions. Selection of the phase
uses the calibration of each of the phase shifters to deter-
mine the phase setting needed for each channel to achieve
the desired output phase. Generally, the accuracy of the out-
put phase is within 10 to comply with the ESHO QA guide-
lines [42]. If the lag phase error of all three channels, on for
example the anterior channel, was 20 more than it should
be, it would cause an effective steering error of 1 cm.
Canters et al. determined that a steering error of 1 cm was
acceptable for clinical work, since this malpositioning will
create a maximum deviation of 5% in the hotspot SAR to
tumor SAR quotient (HTQ) [43]. Lee et al. evaluated the
power and phase stability of the BSD-2000-3D system over a
duration of one year [44], showing that the variation in
power was less than 0.22 dB (5.2%) and the variation in
phase measurements was 1.18 or less. Nevertheless, it is
important to note that while phase errors of 10 20, which
may not impair a 2D-pattern in a homogeneous phantom,
can cause relevant changes in patterns in a heterogeneous
3D- phantom [22,23,45].
The intention of the present study is to compare the simi-
larity of the performance of the MR-HT systems as they are
used in the clinic. During this work, the heating was applied
according to the QA instructions of the local hospital. Focus-
steering of the applicator was assessed for a centric target at
a (0, 0) cm location and for an eccentric target at a (3, 0) cm
at the system console. Measurements were performed by
applying equal power to each of the twelve channels of the
applicator, with a total clinically relevant power of 600W.
Spoiled gradient recalled echo (GRE) sequences with two
echo times (double echo) were used as provided by the
manufacturer for clinical applications. A high-resolution scan
was used to support the positioning of the phantom, detect
air pockets inside the bolus, and facilitate segmentation of
fat-like references attached inside the applicator to compen-
sate for B0 drift [17]. Two MRT scans were performed as
baseline without heating. Afterwards, eight sequential MRT
scans were acquired with the power on, as shown in Figure
2(C). MRT was evaluated in the last scan with the power on.
Table 1 shows the main parameters of the scans.
Data analysis
The proton resonance frequency shift (PRFS) method was
used to calculate MR-based thermal maps [17,24,46–48],
which are a dataset of MR temperatures that can be quanti-
tatively compared with direct temperature measurements (in
C). MR temperatures are deduced from phase differences
(corrected for B0 drift) between the baseline scan and the
actual scan. The MR-based thermal maps were obtained from
the PRFS signal using the DTE method as used by Dadakova
et al. [49]. The DTE method corrects for phase changes due
to temperature-induced changes in phantom conductivity,
which would otherwise lead to an overestimation of the tem-
perature change [17]. The Sigma Vision Advance software
(Dr. Sennewald Medizintechnik GmbH, Munich, Germany),
which is based in the PRFS method, was used to calculate
the MR-based thermal maps. The prototype of this software
package (later called Sigma Vision Advance) has previously
been applied and described [21,50]. The PRFS method is the
most widely used MRT method and has been validated ver-
sus temperature probes in phantoms and volunteers
[21,34,51] and is used clinically [19,20,52]. The MR-based
thermal maps were subsequently 3D and quantitatively eval-
uated using Matlab (R2016b) in the axial, sagittal, and cor-
onal views at the end of the heating period. The MR
temperature was normalized to the maximum 98 percentile
at the center of the applicator (axial image) to compensate
for variation in system efficiency and reduce the impact of
MR noise. This value provides the highest MR temperature
within the 1.3 C uncertainty value of repeatability in a cylin-
drical phantom [17] for a centric target. Iso-contours at 90%,
75%, and 50% of the normalized MR temperature
were generated.
Results
Experimental conditions varied due to the different lengths
of cables used to connect the RF amplifiers and antennas of
each system, and consequently, the RF power lost in the
cables differed among the systems. By normalizing, the vari-
ability in system efficiency does not have an impact on the
heating performance.
Table 1. Main parameters of the MR-sequences as used in the different institutions.
Sequence
TR
(ms) TE1 (ms)
TE2
(ms)
FA
(deg) Acquisition matrix Reconstruction matrix Scan time (sec)
Institution 1 High-resolution MR scan 120 4.8 9.60 70 256/256 256/256 136
MRT 620 4.8 19.1 40 128/128 256/256 83
Institution 2
Institution 4
Institution 5
High-resolution MR scan 120 4.76 9.53 70 256/256 256/256 124
MRT 600 4.76 19.10 50 128/128 128/128 78
Institution 3 High-resolution MR scan 120 4.60 9.21 70 252/250 256/256 151
MRT 600 4.60 18.42 50 128/128 256/256 79
All scans were performed with the following parameters: 25 axial slices; 10-mm slice thickness, and an FOV of 50 50 cm.
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The collected water samples presented a permittivity and
effective conductivity standard deviation at 100MHz of ± 0.1
and ± 8.3 mS/m, respectively. The room and water bolus tem-
perature prior to each measurement was 22.3 ± 1.5 C and
19.9 ± 2.1 C, respectively.
Measurements were performed successfully in all institu-
tions and the results allowed comparison. Figure 3 shows
the normalized MR-based thermal maps at the five institu-
tions for centric targets. All maps featured comparable heat-
ing in the centric region and top part of the pelvic bones.
Figure 3. Normalized MRT distribution for centric targets. Axial, sagittal, and coronal cross-sections are plotted at the center of the field of view (white lines). Iso-
contours at 90% (red), 75% (blue), and 50% (yellow) are shown. The center of the heating target is indicated with ‘’ in all cross-sections.
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Besides these common features, the MRT maps for
Institution 1 showed a centrally located focus within the pel-
vic bones in the axial view; a focus centrally located above
the spine in the sagittal view; and two well-defined foci on
both sides of the spine in the coronal view. The phantom in
Institution 2 was shifted 9.8mm in the ventral direction with
respect to the average phantom position in all the experi-
ments. The axial view indicates a centrally located focus;
however, the sagittal view indicates a cranial shift in the
focus. The coronal view indicates a preferential heating on
the right side. Institution 3 showed a centric focus in all
three planes. The system in Institution 4 exhibited centrally
located and off-target heating in the dorsal area, which can
be seen in both the axial and sagittal view. While the focus
is centrally located in the coronal view, a slight shift toward
the feet of the phantom can be seen in the sagittal view.
The system in Institution 5 showed preferential heating
toward the phantom’s left in the axial and coronal view.
Table 2 shows a quantitative comparison of the 50% iso-con-
tours in the axial, sagittal, and coronal cross-sections. The
clinical relevance of the differences in the 50% iso-contours,
together with the visual assessment of the heating perform-
ance of the applicator, is described in Table 3.
Figure 4 shows the MR-based temperature distributions
obtained for the eccentric heating target. In all thermal
maps, the core heating pattern was located within the vol-
ume enclosed by the pelvic bones, with a clear focus toward
the patient’s left side. For all institutions, a secondary focus
Table 2. Surface enclosed by the iso-contours for the axial, sagittal, and coronal views of the centric and eccentric targets.
Centric target (0,0) cm
Axial 50% surface (cm2) Sagittal 50% surface (cm2) Coronal 50% surface (cm2)
Institution 1 195.75 92.17 95.98
Institution 2 157.88 74.83 80.46
Institution 3 200.47 82.44 78.03
Institution 4 224.96 92.48 81.83
Institution 5 158.49 57.03 69.97
Mean 195.75 82.44 80.46
Standard deviation 28.98 14.70 9.43
Eccentric target (3,0) cm
Axial 50% surface (cm2) Sagittal 50% surface (cm2) Coronal 50% surface (cm2)
Institution 1 146.47 54.15 59.47
Institution 2 188.30 65.10 89.89
Institution 3 177.04 78.18 94.15
Institution 4 270.43 100.08 112.40
Institution 5 124.87 36.05 51.56
Mean 177.04 65.10 89.89
Standard deviation 55.70 24.22 25.33
Table 3. Comparison of the heating performance of the applicator in the various institutions with respect to that of the applicator in Institution 1, for both cen-
tric and eccentric targets.
Centric target (0,0) cm
Institution Axial Sagittal Coronal Average score
2 3 2 (cranial shift of primary focus) 1 (smaller primary focus due
to ventral misalignment of
phantom and secondary hotspot)
2
3 3 3 2 (smaller primary focus) 3
4 2 (dorsal secondary focus) 2 (dorsal secondary focus) 2 (larger primary focus) 2
5 1 (preferential heating
toward patient’s left,
smaller primary focus)
2 (smaller focus due to
preferential heating
toward patient’s left)
2 (preferential heating
toward patient’s left)
2
Eccentric target (3,0) cm
Institution Axial Sagittal Coronal Average score
2 3 2 (cranial shift of primary focus) 1 (smaller primary focus due
to ventral misalignment
of phantom, secondary focus)
2
3 3 3 2 (smaller primary focus) 3
4 2 (dorsal secondary focus) 1 (larger primary focus,
dorsal secondary focus)
2 (larger primary focus) 2
5 2 (preferential heating
toward patient’s left)
0 (smaller focus due to
preferential heating
toward patient’s left,
dorsal secondary hotspots,
ventral secondary hotspots)
1 (preferential heating
toward patient’s left,
secondary focus)
1
Three types of difference are observed in the heating patterns: a shift of the primary heating focus, a change in the size of the primary focus, and the gener-
ation of a secondary focus. Scores for the quantitation of the observed differences are given according to: 3 (similar heating patterns); 2 (one type of difference
between the heating patterns); 1 (two types of difference between the heating patterns); and 0 (three types of difference between the heating patterns). The
observed differences are indicated in brackets.
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was found on the upper part of the left pelvic bone. The
sagittal view shows an expected, diminished heating pattern
as compared with Figure 3 due to the change in target loca-
tion. The maps for Institution 1 show a well-defined focus at
the eccentric target location in the axial and coronal view.
The phantom at Institution 2 was shifted 11.7mm in the
ventral direction with respect to the average phantom pos-
ition in all the experiments. The heating pattern had a distri-
bution comparable with Institution 1. Due to the shifted
position of the phantom, the coronal view only provides the
peripheral heating of the focus. The thermal maps for
Institution 3 in the axial plane exhibited similar heating to
Figure 4. Normalized MRT distribution for eccentric targets. Axial, sagittal, and coronal cross-sections are plotted at the center of the field of view (white lines).
Iso-contours at 90% (red), 75% (blue), and 50% (yellow) are shown. The center of the heating target is indicated with ‘’ in the axial and coronal cross-sections.
Note that the sagittal cross-section is through the center of the field of view.
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Institutions 1 and 2. Institution 4 showed preferential heating
toward the eccentric left target; however, off-target heating
in the posterior of the phantom and above the left pelvic
bone was also observed. Lastly, the MR temperature distribu-
tion for Institution 5 showed the highest focus shift toward
the left side; additionally, an off-target secondary focus was
found in the area of the os-pubis.
Discussion
In this work, the performance of clinically used MR-guided
HT applicators was systematically evaluated in five European
institutions in Germany and The Netherlands. While inde-
pendent QA measurements are performed in each institution
using basic cylindrical phantoms, no comparison of the dif-
ferent systems has been reported to date. The aim of the
present study, therefore, was to investigate the system
performance regarding heating capabilities under clinical
patient conditions. Hereto, new dedicated phantoms with a
realistic human shape, including artificial bone structures,
were developed. These phantoms were transported to the
different institutions, where the same experimental setup
was applied for the QA measurements performed by the
same principal investigator supported by local investigators.
Measurements were performed to evaluate the heating capa-
bilities of the systems to treat tumors centrally and eccentric-
ally located in the pelvic region.
Thermal maps (Figures 3 and 4) show comparable heating
distribution of all applicators. The location of the heating
focus was generally well correlated with the set centric and
eccentric targets. Off-target heating between the ‘legs’ was
observed in all the institutions, which was caused by the fact
that the water bolus could not fill the volume between the
‘legs’, in addition to potential artifacts resulting from FOV
border effects. During clinical treatment, an extra water bolus
Figure 5. Temporal evolution of the temperature increase determined by high-resistance thermistor probes for centric and eccentric heating targets. The positions
of the probes in the phantom are indicated by numbers and colored squares in the MR image showing the cross-section of the phantom and the surrounding
water bolus. The target location is indicated by a yellow circle. A comparison between MRT and thermistor probes for the different institutions can be found in
Curto et al. [24].
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is positioned between the legs of the patient to mitigate this
effect. At Institution 4, off-target heating was observed at
the dorsal part of the phantom for both the centric and
eccentric target. As many interrelated factors may generate
this effect, such as phase-induced errors [22,23,45], coupling
between antennas, mismatching of antennas, or poor cable
connections leading to an unexpected applicator perform-
ance, the origin of this secondary focus remains unexplained.
For the centric as well as the eccentric target, a secondary
focus adjacent to the left ala of the ileum (ala ossis ilii), near
to the left iliac spine (spina iliaca ant. sup.), was found, which
was more pronounced for the eccentric target. This has also
been previously described by Canters et al., [53] and can
lead to patient complaints regarding that area. Figure 5
shows the thermistor probe measurements for centric and
eccentric targets. A linear temperature increase was observed
for both target locations. For the centric target (Figure
5(A,B)), a similar temperature increase was measured for all
thermistor probes (maximum difference in temperature
increase between the probes was within 1 C); however, for
the eccentric target (Figure 5(C,D)), the temperature differ-
ence between the more distant probes (green and black
curves) reached 4.1 C, illustrating the steering capabilities of
the system. A quantitative evaluation performed at the five
institutions showed good agreement between MRT and ther-
mistor probe measurements [24]. For all institutions, a linear
relationship was found between MRT and thermistor probe
measurements, with an R2 (mean± standard deviation) of
0.97 ± 0.03 and 0.97 ± 0.02 for centric and eccentric heating
targets, respectively. The RMSE was found to be
0.52 ± 0.31 C and 0.30 ± 0.20 C, respectively. The
BlandAltman evaluation showed a mean difference of
0.46 ± 0.20 C and 0.13 ± 0.08 C, respectively.
Although MR provides the best imaging approach, varia-
tions in phantom position or tilting can have a non-negli-
gible impact on the obtained heating pattern of one of the
measurement cross-sections; therefore, careful evaluation of
the measured heating patterns is needed to differentiate
between applicator and positioning effects. This is especially
relevant for anthropomorphic phantoms, where a small pos-
ition shift may have strong effects on the visualized heating
patterns due to the differences in dielectric properties of the
various materials. Such effects are normally not seen or are
less pronounced in homogeneous phantoms. In clinical situa-
tions, these effects are generally averaged out by constant
and small patient movements. An interpretation of the heat-
ing performance of the different applicators in comparison
with the applicator in Institution 1 is provided in Table 3.
Additionally, it is important to note that the anthropo-
morphic phantom used in the present study has sharp elec-
trical boundaries between the bones and the phantom tissue
mixture, which may be less pronounced in patients. The
influence of electrical boundaries on the generated heating
patterns has been identified in previous publications [29]. In
a recent study [17], we performed QA measurements with an
ideal set up using the same applicator and a homogeneous
phantom. This study showed that despite the phantom
being precisely positioned and fixed in wooden stands, there
was a shift in the focus by 1 cm between different measure-
ments. Previous publications [22,23] have demonstrated that
phase and amplitude deviations at the antenna feed point
and inaccuracies in positioning were important sources of
error. The present study strongly suggests that the impact of
phantom position accuracy should be further evaluated, and
future standards should be developed to provide indications
regarding how to compare the performance of different
applicators. Moreover, if better control of phases and ampli-
tudes is achieved at the antenna feed points, more accurate
prediction of the heating pattern is possible, and hence, a
better controlled treatment is obtained.
Different applicator settings can be implemented to coun-
teract specific applicator performance. For example, at
Institution 4, the power on the top and bottom antennas is
decreased by 2030% under clinical operation to reduce the
heating on the top and lower parts of the patient. This com-
pensation practice is guided by local QA testing and was
purposely not used in the present study, in which the same
power was applied to all antennas. Certain phase offsets can
be predefined in the applicator to correct deviations in the
obtained focus heating, and have been used for compensa-
tion in the current practice using the 3D-MR testing of gel-
filled cylindrical phantoms. Verification of the effectiveness of
these measures is the responsibility of the institutions and
was not part of the present study.
The newly developed phantom with a realistic detailed
human shape proved to be a valuable tool to periodically
perform QA measurements validating the performance of the
systems and to train the hyperthermia clinical team. The
inclusion of bones and irregular shapes in the phantom is
considered conducive to more clinically relevant heating pat-
terns as compared with a homogeneous phantom [17]. The
advantage of a more clinically relevant heating is that a real-
istic evaluation can be made; however, the evaluation is
more dependent on the accurate positioning of the phan-
tom. While the same phantoms and measurement settings
were applied, there are a series of uncertainties inherent to
this evaluation. As previously described by Gellermann et al.
[22] and Weihrauch et al. [23], important sources of uncer-
tainties in these applicators are phase errors at the feed
point of the antennas. While the positioning of the phantom
was within the ±10mm guidelines for non-MR-guided hyper-
thermia [27], except for eccentric target in Institution 2
where the phantom was 11.7mm from the average position,
this work shows that a more accurate positioning procedure
may be necessary, especially when evaluating the results
with a high-resolution system such as an MR system. Despite
the comparison of the results having been performed along
the three main axes (axial, sagittal, and coronal), further eval-
uations should consider a full 3D data analysis. To facilitate a
full 3D evaluation of newly acquired data, an improved and
more rigid phantom positioning should be implemented.
Secondly, due to the requirement of performing only one
measurement per day in the same phantom (necessary cool-
ing of the phantom after an experiment), only a limited
number of measurements were possible, and therefore only
one QA measurement per setup was performed in each of
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the five institutions. However, multiple measurements for
each phantom setup would be required in order to evaluate
the reproducibility of the results [17]. MRT data was collected
during baseline and heating period. Further work should
evaluate the collection of MRT data also during the cooling
down period to show return to baseline temperature in
order to demonstrate the effectiveness of the procedure to
correct for field drift. Lastly, while the present study suggests
that the Universal Applicator has a performance comparable
with Sigma-Eye applicators, follow-up work should demon-
strate whether this applicator will lead to higher QA compar-
ability between systems.
The present study is the first to best ensure comparable
performance of MR-compatible hyperthermia applicators
using 3D-measurement of the MR temperature distribution
in a realistic heterogeneous phantom. This work provides
insight into the comparable performance of both MR-com-
patible hyperthermia systems for current clinical treatments,
depending upon applicator-specific characteristics and pre-
cise patient positioning. The current study in representative
phantoms indicates that unnoticed variation can be present
in the applied hyperthermia between institutions, systems,
different patients, and intra-individually between sequential
treatment sessions. Hence, when compiling a 3D-visualisation
obtained by multiple 2D measurements with associated
sequential construction of the measurement, set-up errors
noted in the present study will be strongly amplified and
seriously affect the accuracy of the resulting 3D heating pat-
terns. The value of the information made available in this
manuscript lies in its ability to demonstrate that the experi-
ence obtained by historical 1D and 2D QA measurements
cannot be directly translated to QA guidelines based on 3D
measurements. In addition, the current study shows that if
the hyperthermia society wants to progress to accurate
quantitative comparison of the 3D temperature profiles
obtained by MRT, a step has to be made toward precision of
the positioning of the phantom in the applicator. Moreover,
an in-depth discussion is needed regarding how to translate
clinical experience with variations in phases at the antenna
feed point and antenna cross-talk. In current hyperthermia
treatment, modeling these effects is not incorporated but
undoubtedly adds to the uncertainty in translating the pre-
dicted energy to the clinical situation. This manuscript aimed
to initiate such discussion toward a deeper evaluation of the
clinically used systems and to reinforce the necessity of spe-
cific guidelines for deep MR-HT systems. Future efforts
should incorporate this new knowledge when designing new
QA guidelines and recommend the highest level QA
tools available.
Conclusions
This investigation reports the first international multi-institu-
tion QA evaluation of MR-guided hyperthermia systems for
the treatment of deep-seated tumors using radiofrequency
applicators. A novel anthropomorphic phantom was devel-
oped to evaluate the performance of the systems.
Comparable heating distribution was assessed using MRT-
derived thermal maps for both centric and eccentric targets.
However, subcentimeter differences in positioning when per-
forming QA measurements in heterogeneous phantoms were
found to substantially affect the resulting heating patterns in
the cross-sectional planes, which complicates the accurate
evaluation of the 3D heating patterns, underlining the
demands for positioning accuracy. The integration of phase
and amplitude evaluation at the feed points, advanced phan-
toms, and precise positioning into current and future QA
procedures should be evaluated to guarantee the best pos-
sible quality of patient care.
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